News

The halted trails also include the large-scale, pivotal and multi-country phase 3 ENSEMBLE trial of the company’s Covid-19 vaccine candidate called JNJ-78436735, which is being developed by Janssen

True North met both primary endpoints, demonstrating highly statistically significant and clinically meaningful results for clinical remission compared to placebo at induction at Week 10 (18.4% versus 6.0%;

ASC42 is an in-house developed novel non-steroidal, selective, potent Farnesoid X Receptor (FXR) agonist with best-in-class potential. In two NASH animal models, ASC42 demonstrated significant improvements in liver

The phase 3 PENELOPE-B trial has failed to achieve the primary endpoint of improved invasive disease-free survival (iDFS) in women with hormone receptor-positive (HR+), human epidermal growth factor-negative

The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), along with Inova Health System, has sponsored the trial. Fostamatinib, which is sold

NOXCOVID-1 is looking at treating those COVID-19 patients hospitalized with moderate lung dysfunction requiring low oxygen support who are at risk of progressing rapidly into requiring intensive care

The deal also includes an option that allows supply of up to 200 million additional doses to the EU member states. This agreement was signed after the conclusion

AFFINE is a global Phase 3, open-label, multicenter, single arm study that will evaluate the efficacy and safety of giroctocogene fitelparvovec in patients with moderately severe to severe

With the IND approval in place, the company expects to launch a phase 2b/3 sequential clinical trial of AB201 in the fourth quarter of 2020. The phase 2b